for breakthrough work on immunity
F
OR THEIR PIONEERING work in innate and
adaptive immunity, Bruce A. Beutler, Jules A. Hoffmann, and the late Ralph M. Steinman were awarded the 2011 Nobel Prize in Physiology or Medicine. These fields of research have revealed how our bodies detect, fight, and remember invading pathogens. Hours after the foundation announced that one-half of the prize would go to Steinman, a Rockefeller University immunologist, the university’s president contacted the foundation to say that Steinman had passed away just three days prior, at age 68. After some deliberation, the Nobel Foundation decided that Steinman will remain a laureate, despite foundation rules barring posthumous prizes. The three prizewinners’ research “has opened up new avenues for the development of prevention and therapy against infections, cancer, and inflammatory diseases,” notes the Nobel Prize announcement. Hoffmann and Beutler will each receive one-quarter of the roughly $1.5 million for their work in the 1990s on innate immunity, which is the body’s first line of defense against invading pathogens. Hoffmann, 70, of France’s National Center for Scientific Research (CNRS) in Strasbourg, discovered that fruit flies that lacked the gene for a receptor protein called Toll died during bacterial and fungal invasions. It turns out that the Toll receptor is a fruit fly’s first line of defense against foreign invaders; Toll’s activation leads to the destruction of the pathogen and the
Beutler CN RS
AWARDS: Three researchers share prize
triggering of an inflammation response that further blocks microbial attack. Two years after Hoffmann’s 1996 discovery of Toll, Beutler, 53, currently a geneticist at the University of Texas Southwestern Medical Center and the Scripps Research Institute, discovered the fruit fly receptor’s equivalent in mice, which he named Toll-like receptor. These two receptors “were the tip of the iceberg,” says Felix Randow, who studies innate immunity at MRC Laboratory of Molecular Biology in Cambridge, England. With Toll and Toll-like receptor in hand, researchers soon managed to identify other components of the innate immunity network, he adds. Steinman is one of the prizewinners for his discovery of the role dendritic cells play in adaptive immunity, the body’s second line of defense against invading pathogens. After the initial detection of foreign invaders by the Toll or Toll-like receptors, dendritic cells process the danger signals from these receptors and then instruct other immune cells called T cells to fight infection and develop a memory of the invading pathogen, says Alexander G. Betz, who studies adaptive immunity at MRC Laboratory of Molecular Biology. When he first heard Steinman had won the prize, Andreas Pichlmair, immunologist at the Max Planck Institute for Biochemistry in Martinsried, Germany, says he felt “more than happy.” “I knew that Ralph Steinman was very sick, and therefore I was happy he got the prize in time. Apparently not. It’s very sad,” he Steinman adds.—SARAH EVERTS
Hoffmann
ROCKEFELLER U
NOBEL PRIZE IN PHYSIOLOGY OR MEDICINE
SCR IP PS R ESEARCH IN ST IT U T E
NEWS OF THE WEEK
CONTRACT RESEARCH Pharmaceutical Product Development to go private in $3.9 billion deal Pharmaceutical Product Development (PPD) has agreed to be purchased by the private equity firms Carlyle Group and Hellman & Friedman in an all-cash transaction valued at $3.9 billion. On completion of the deal, heralded as a sign of things to come in the contract research sector, PPD will become a private company. With sales last year of $1.5 billion, PPD is one of the world’s largest pharmaceutical contract research organizations. PPD, in recent years, has extended
its scope to cover a broad range of drug discovery and development services. In 2009, for example, PPD acquired BioDuro, a California-based drug discovery services firm employing about 660 chemists and other research staff, mainly in Beijing. Lauren Migliore, a stock analyst with Morningstar, tells C&EN that the breadth of services offered by PPD is part of what attracted the private investors. “Having early discovery through Phase IV services is one of the primary reasons why PPD has been so successful at winning new
WWW.CEN-ONLINE.ORG
11
OCTOBER 10, 2011
business and landing long-term strategic partnerships,” she says. Migliore anticipates more deals in the contract research sector, where the last major player to be taken private, Quintiles, was acquired by its founder and a team of private investors in 2003. She says larger players like Covance, Parexel, and Charles River are poised for growth based on increased outsourcing by pharmaceutical firms, as well as market share gains at the expense of their smaller peers.—RICK MULLIN
